Breast cancer outcome in relation to bone mineral density and bisphosphonate use: a sub-study of the DATA trial
ConclusionNo association was observed between a reduced BMD and DRFS. Neither did we observe an impact of bisphosphonates on DRFS. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - March 2, 2020 Category: Cancer & Oncology Source Type: research

Anastrozole/exemestane/letrozole
(Source: Reactions Weekly)
Source: Reactions Weekly - March 1, 2020 Category: Drugs & Pharmacology Source Type: research

Anastrozole has an association between degree of estrogen suppression and outcomes in early breast cancer and is a ligand for estrogen receptor α.
CONCLUSIONS: This matched case-control clinical study revealed that levels of estrone and estradiol above identified thresholds after six months of adjuvant anastrozole treatment were associated with increased risk of an EBCE. Preclinical laboratory studies revealed that anastrozole, but not exemestane or letrozole, is a ligand for estrogen receptor a. These findings represent potential steps towards individualized anastrozole therapy. PMID: 32098767 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - February 25, 2020 Category: Cancer & Oncology Authors: Ingle JN, Cairns J, Suman VJ, Shepherd LE, Fasching PA, Hoskin TL, Singh RJ, Desta Z, Kalari KR, Ellis MJ, Goss PE, Chen BE, Volz B, Barman P, Carlson EE, Haddad TC, Goetz MP, Goodnature B, Cuellar ME, Walters MA, Correia C, Kaufmann SH, Weinshilboum RM, Tags: Clin Cancer Res Source Type: research

Anastrozole Benefits in High-Risk Patients Persist for Years
No abstract available (Source: Oncology Times)
Source: Oncology Times - February 20, 2020 Category: Cancer & Oncology Tags: News Source Type: research

Benign leiomyoma with multiple metastases to vertebrae and calvarium: An index case with comprehensive review of endocrine targets
Abstract“Benign” metastatic leiomyomas (BML) are indolently growing metastatic tumors which mostly associate with uterine leiomyomas in women in reproductive ages. The reason to define these lesions as “benign” despite metastasis is their pathological features with low mitotic counts, lack of or min imal nuclear atypia, pseudocyst formation, and coagulative necrosis unlike leiomyosarcomas. Despite lack of pathological malignant features, they may cause significant morbidity and even mortality. Here, we describe a BML case with metastases to vertebrae and skull bones. Vertebral and skull metasta ses ...
Source: Neurosurgical Review - February 20, 2020 Category: Neurosurgery Source Type: research

First-line endocrine therapy for postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysis.
CONCLUSION: In the first-line treatment for advanced postmenopausal hormone receptor-positive breast cancer, a combination therapy of CDK4/6 inhibitors and AI showed significant improvement of PFS, ORR, and CBR but with significant increased toxicities compared with AI alone. Fulvestrant 500 mg monotherapy significantly prolonged PFS compared with AI monotherapy. We must wait for the results of the studies with longer follow-up period. PMID: 32043218 [PubMed - as supplied by publisher] (Source: Breast Cancer)
Source: Breast Cancer - February 11, 2020 Category: Cancer & Oncology Authors: Shimoi T, Sagara Y, Hara F, Toyama T, Iwata H Tags: Breast Cancer Source Type: research

Anastrozole plus fulvestrant vs. anastrozole alone for hormone receptor-positive advanced breast cancer: a meta-analysis of randomized controlled trials
ConclusionsFor HR-positive advanced breast cancer patients, the combination of anastrozole and fulvestrant appears to be superior to anastrozole alone in extending PFS and OS, despite relatively serious AEs. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 1, 2020 Category: Cancer & Oncology Source Type: research

Anastrozole-Induced Dermatitis: Report of a Woman with an Anastrozole-Associated Dermatosis and a Review of Aromatase Inhibitor-Related Cutaneous Adverse Events
AbstractAnastrozole is an aromatase inhibitor. Anastrozole competitively inhibits the aromatase enzyme, which synthesizes estrogen. It is used for estrogen receptor-positive breast cancers. A woman with breast cancer and anastrozole-induced dermatitis is described; the cutaneous side effects associated with aromatase inhibitors are also reviewed. Skin-related adverse events associated with aromatase inhibitor use are uncommon and may be delayed in appearance; the time of onset ranges from less than 5  days to 6 months (median 2 months). They present as either vasculitis, erythema nodosum, subacute cutaneous ...
Source: Dermatology and Therapy - January 21, 2020 Category: Dermatology Source Type: research

Comparative effectiveness of tamoxifen, toremifene, letrozole, anastrozole, and exemestane on lipid profiles in breast cancer patients: A network meta-analysis
Conclusion: The findings of this study will be published in a peer-reviewed journal. Prospero Registration Number: CRD42019129850. (Source: Medicine)
Source: Medicine - January 1, 2020 Category: Internal Medicine Tags: Research Article: Study Protocol Systematic Review Source Type: research

Anastrozole-induced pulmonary cryptococcosis in a patient with early breast cancer: A case report
Conclusion: This case of pulmonary cryptococcosis may have been induced by a decrease in estrogen level caused by the aromatase inhibitor, anastrozole. Treatment of pulmonary cryptococcosis with concurrent anastrozole use may be ineffective, and it may be better to discontinue the aromatase inhibitor. (Source: Medicine)
Source: Medicine - January 1, 2020 Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research

First-line fulvestrant plus anastrozole for hormone-receptor-positive metastatic breast cancer in postmenopausal women: a cost-effectiveness analysis.
CONCLUSION: Substituting fulvestrant as a first-line therapy for hormone-receptor-positive metastatic breast cancer is not cost-effective compared with anastrozole based on the willing-to-pay threshold of $150,000 per QALY. PMID: 31853795 [PubMed - as supplied by publisher] (Source: Breast Cancer)
Source: Breast Cancer - December 18, 2019 Category: Cancer & Oncology Authors: Liao W, Huang J, Wu Q, Wen F, Zhang N, Zhou K, Bai L, Li Q Tags: Breast Cancer Source Type: research

Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial
Publication date: Available online 12 December 2019Source: The LancetAuthor(s): Jack Cuzick, Ivana Sestak, John F Forbes, Mitch Dowsett, Simon Cawthorn, Robert E Mansel, Sibylle Loibl, Bernardo Bonanni, D Gareth Evans, Anthony Howell, IBIS-II investigatorsSummaryBackgroundTwo large clinical trials have shown a reduced rate of breast cancer development in high-risk women in the initial 5 years of follow-up after use of aromatase inhibitors (MAP.3 and International Breast Cancer Intervention Study II [IBIS-II]). Here, we report blinded long-term follow-up results for the IBIS-II trial, which compared anastrozole with placebo...
Source: The Lancet - December 13, 2019 Category: General Medicine Source Type: research

Rethinking the combination treatment of fulvestrant and anastrozole for metastatic breast cancer: an integrated reanalysis of aromatase –estrogen receptor axis
Aberrant expression or hyperactivation of aromatase (CYP19A1) –estrogen receptor (ESR) axis is well identified as one of the major causes of breast cancer. Lots of drugs have been developed for targeting CYP19A... (Source: Clinical and Translational Medicine)
Source: Clinical and Translational Medicine - November 18, 2019 Category: Internal Medicine Authors: Xing Huang Tags: Commentary Source Type: research

M166 estrogen-dependent angioedema responsive to anastrozole in a male with familial hyperestrogenemia and hereditary cancer risk
A 44-year-old man was evaluated for recurrent angioedema manifested as more than 10 discrete episodes with swelling of the posterior pharynx and uvula, without urticaria, that would subside spontaneously over 24 hours. These episodes were first noted 2 years ago, were worsened by alcohol, and were not responsive to antihistamines. Medical history was significant for hyperestrogenism, that worsened with testosterone treatment for infertility. His primary family history revealed a father and brother with gynecomastia, a mother with endometrial cancer, and a sister with Lynch syndrome. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2019 Category: Allergy & Immunology Authors: P. Staso, C. Vethody, C. Stone, E. Phillips Source Type: research

Validation of the OncoMasTR Risk Score in Estrogen Receptor-Positive/HER2-Negative Patients: a TransATAC study.
Abstract PURPOSE: To test the validity of OncoMasTR Molecular Score (OMm), OMclin1 and OncoMasTR Risk Score (OMclin2) prognostic scores for prediction of distant recurrence (DR) in ER-positive/HER2-negative breast cancer treated with 5 years' endocrine therapy only and compare their performance with the Oncotype DX Recurrence Score (RS). EXPERIMENTAL DESIGN: OMm incorporates three Master Transcription Regulator genes. OMclin1 combines OMm, tumor size, grade, nodal status; OMclin2 incorporates OMm, tumor size, nodal status. OMclin1 and OMclin2 were evaluated for 646 postmenopausal patients with ER-positive/HER...
Source: Clinical Cancer Research - October 22, 2019 Category: Cancer & Oncology Authors: Buus R, Sestak I, Barron S, Loughman T, Fender B, Ruiz CL, Dynoodt P, Wang CA, O'Leary D, Gallagher WM, Dowsett M, Cuzick J Tags: Clin Cancer Res Source Type: research

Potent cell cycle inhibition and upregulation of immune response with abemaciclib and anastrozole in neoMONARCH, Phase 2 neoadjuvant study in HR+/HER2- breast cancer.
on DJ Abstract PURPOSE: neoMONARCH assessed the biological effects of abemaciclib in combination with anastrozole in the neoadjuvant setting. EXPERIMENTAL DESIGN: Postmenopausal women with stage I-IIIB HR+/HER2-   breast cancer were randomized to a 2-week lead-in of abemaciclib, anastrozole, or abemaciclib plus anastrozole followed by 14 weeks of the combination. The primary objective evaluated change in Ki67 from baseline to 2 weeks of treatment. Additional objectives included clinical, radiologic, and pathologic responses, safety, as well as gene expression changes related to cell proliferation and im...
Source: Clinical Cancer Research - October 15, 2019 Category: Cancer & Oncology Authors: Hurvitz SA, Martín M, Press MF, Chan D, Fernandez-Abad M, Petru E, Rostorfer R, Guarneri V, Huang CS, Barriga S, Wijayawardana SR, Brahmachary M, Ebert PJ, Hossain A, Liu J, Abel A, Aggarwal A, Jansen VM, Slamon DJ Tags: Clin Cancer Res Source Type: research

A systematic review and meta-analysis of clinical trials implementing aromatase inhibitors to treat male infertility.
Abstract Aromatase activity has commonly been associated with male infertility characterized by testicular dysfunction with low serum testosterone and/or testosterone to estradiol ratio. In this subset of patients, and particularly in those with hypogonadism, elevated levels of circulating estradiol may establish a negative feedback on the hypothalamic-pituitary-testicular axis by suppressing follicle-stimulating hormone (FSH) and luteinizing hormone (LH) production and impaired spermatogenesis. Hormonal manipulation via different agents such as selective estrogen modulators or aromatase inhibitors to increase end...
Source: Asian Journal of Andrology - October 15, 2019 Category: Urology & Nephrology Authors: Giudice FD, Busetto GM, De Berardinis E, Sperduti I, Ferro M, Maggi M, Gross MS, Sciarra A, Eisenberg ML Tags: Asian J Androl Source Type: research

386TiPRIbociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with HR+, HER2 – inoperable locally advanced or metastatic breast cancer: RIGHT choice study
AbstractBackgroundA high percentage of breast cancer patients in the Asia-Pacific ( ∼42%) and Middle East (∼50%) regions are aged 50 years or younger. Although a high proportion of younger patients with endocrine-responsive metastatic disease are treated initially with cytotoxic chemotherapy (CT) in routine general practice, data from phase III trials have shown higher response rates and longer progression-free survival with endocrine therapy (ET) in combination with CDK4/6 inhibitor versus single agent ET. Due to lack of direct evidence, trials in pre-/perimenopausal advanced breast cancer are thus necessary to as...
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research

326PMONARCH 3: Updated time to chemotherapy and disease progression following abemaciclib plus aromatase inhibitor (AI) in HR+, HER2- advanced breast cancer (ABC)
AbstractBackgroundIn MONARCH 3, a randomized, double-blind, phase 3 trial; continuous dosing of abemaciclib in combination with an AI (anastrozole or letrozole) conferred significant clinical benefit to postmenopausal women with HR+, HER2- ABC. We here report data from an additional 12 months of follow-up in this trial including analysis for clinically prognostic subgroups (Di Leo et al., 2018).MethodsFrom the 31 October 2018 data cutoff, exploratory intermediate efficacy parameters including time to subsequent chemotherapy ([TCT] time from randomization to first chemotherapy [CT]) and time to second disease progression ([...
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research

308PDUpdated overall survival (OS) and quality of life (QoL) in premenopausal patients (pts) with advanced breast cancer (ABC) who received ribociclib (RIB) or placebo (PBO) plus goserelin and a nonsteroidal aromatase inhibitor (NSAI) in the MONALEESA-7 (ML-7) trial
AbstractBackgroundRIB plus an NSAI is indicated for premenopausal pts with hormone-receptor –positive (HR+), HER2− ABC based on data from the ML-7 trial (NCT02278120), including progression-free survival (PFS), which was longer with RIB vs PBO (median 23.8 vs 13.0 months; HR 0.55; P 
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research

A Combined Treatment for a Case of Peri-Implant Bisphosphonate-Related Osteonecrosis of the Jaw.
CONCLUSIONS: A combined therapy aiming at regeneration of bone and soft tissues around osseointegrated implants was successful for treatment of implant-associated BRONJ. PMID: 31473719 [PubMed] (Source: Journal of the International Academy of Periodontology)
Source: Journal of the International Academy of Periodontology - September 4, 2019 Category: Dentistry Tags: J Int Acad Periodontol Source Type: research

Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update.
Abstract PURPOSE: To update the ASCO guideline on pharmacologic interventions for breast cancer risk reduction and provide guidance on clinical issues that arise when deciding to use endocrine therapy for breast cancer risk reduction. METHODS: An Expert Panel conducted targeted systematic literature reviews to identify new studies. RESULTS: A randomized clinical trial that evaluated the use of anastrozole for reduction of estrogen receptor-positive breast cancers in postmenopausal women at increased risk of developing breast cancer provided the predominant basis for the update. UPDATED RECOMMENDATIO...
Source: Clinical Genitourinary Cancer - September 3, 2019 Category: Cancer & Oncology Authors: Visvanathan K, Fabian CJ, Bantug E, Brewster AM, Davidson NE, DeCensi A, Floyd JD, Garber JE, Hofstatter EW, Khan SA, Katapodi MC, Pruthi S, Raab R, Runowicz CD, Somerfield MR Tags: J Clin Oncol Source Type: research

Deep sequencing across germline genome-wide association study signals relating to breast cancer events in women receiving aromatase inhibitors for adjuvant therapy of early breast cancer
Conclusion We were unable to identify common or rare variant regions that added value to the findings from our previous GWAS. We did find two haplotypes that were significant after adjusting for our top GWAS SNP but these were considered to be of marginal value. (Source: Pharmacogenetics and Genomics)
Source: Pharmacogenetics and Genomics - August 30, 2019 Category: Genetics & Stem Cells Tags: Original Articles Source Type: research

A novel GC-MS methodology to evaluate aromatase activity in human placental microsomes: a comparative study with the standard radiometric assay.
Abstract Estrogens are key factors in the development of the estrogen receptor-positive (ER+) breast cancer. Estrogens, estrone (E1), and estradiol (E2) production is achieved by aromatase, a cytochrome P450 enzyme that has androgens, androstenedione (AD), and testosterone (T) as substrates. Nowadays, third-generation aromatase inhibitors (AIs) are considered the gold-standard treatment for ER+ breast cancer in postmenopausal women as well as in premenopausal women with ovary ablation. Aromatase activity assessment still relies on radiometric assays that are expensive, hazardous, and non-environmentally friendly. ...
Source: Analytical and Bioanalytical Chemistry - August 22, 2019 Category: Chemistry Authors: Augusto TV, Cunha SC, Amaral C, Fernandes JO, da Silva ET, Roleira FFM, Teixeira N, Correia-da-Silva G Tags: Anal Bioanal Chem Source Type: research

Efficacy of denosumab for restoring normal bone mineral density in women receiving adjuvant aromatase inhibitors for early breast cancer
Background: Osteoporosis is a major side effect of aromatase inhibitors (AIs), which are greatly effective in the treatment of breast cancer. However, there are no satisfactory measures against osteoporosis. In this multicenter, randomized, comparative study, we evaluate the efficacy of denosumab for preventing loss of bone mineral density (BMD) induced by adjuvant therapy with AI s in breast cancer patients with normal BMD. Patients and methods: The bone loss-suppressing effect of denosumab will be comparatively evaluated in postmenopausal patients scheduled to receive letrozole or anastrozole as a postoperative endo...
Source: Medicine - August 1, 2019 Category: Internal Medicine Tags: Research Article: Study Protocol Clinical Trial Source Type: research

PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression.
CONCLUSION: A subset of asymptomatic patients with ER⁺ and/or PR⁺ ROC and CA125 progression had durable clinical benefit on anastrozole, with acceptable toxicity. Anastrozole may delay symptomatic progression and the time to subsequent chemotherapy. The future challenge is to identify the subset of patients most likely to benefit from an aromatase inhibitor and whether the clinical benefit could be increased by the addition of other agents. PMID: 31328463 [PubMed - in process] (Source: Journal of Gynecologic Oncology)
Source: Journal of Gynecologic Oncology - July 23, 2019 Category: OBGYN Tags: J Gynecol Oncol Source Type: research

Somatic BRCA2 Mutation-Positive Concurrent Accessory Male Breast Cancer (BC) and Non-Small Cell Lung Cancer (NSCLC): Excellent Efficacy of Palbociclib, Fulvestrant and Leuprolide in Platinum-Exposed and Endocrine-Refractory BC Associated with Cyclin D1 and FGFR1 Amplification and of Carboplatin, Paclitaxel and Radiation in NSCLC
We report a 76-year-old patient who was diagnosed with concurrent accessory breast and primary lung cancer, both were positive for somatic BRCA-2 (E1593D) mutation. He received concurrent radiation and platinum-based chemotherapy for lung cancer with good response, but breast cancer progressed in about 8 months, and further progressed after single agent anastrozole in 10 months. Next Generation Sequencing (NGS) of breast cancer was also positive forCCND1 (Cyclin D1) and FGFR1 amplifications. Despite a poor molecular profile of breast cancer, and progression following platinum-based chemotherapy and anastrozole, he was succ...
Source: Case Reports in Oncology - June 26, 2019 Category: Cancer & Oncology Source Type: research

Agranulocytosis Induced by Tamoxifen in a Breast Cancer Patient
Conclusion: Agranulocytosis is a very rare adverse event of tamoxifen.Breast Care (Source: Breast Care)
Source: Breast Care - June 20, 2019 Category: Cancer & Oncology Source Type: research

PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors.
CONCLUSIONS: Anastrozole was associated with a CBR of 61% of patients with recurrent ER-positive and/or PR-positive LGOC or SBOT for at least 6 months with acceptable toxicity. PMID: 31227223 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - June 18, 2019 Category: Cancer & Oncology Authors: Tang M, O'Connell RL, Amant F, Beale P, McNally O, Sjoquist KM, Grant P, Davis A, Sykes P, Mileshkin L, Moujaber T, Kennedy CJ, deFazio A, Tan K, Antill Y, Goh J, Bonaventura T, Scurry J, Friedlander M Tags: Gynecol Oncol Source Type: research

Effect of local aromatase inhibition in endometriosis using a new chick embryo chorioallantoic membrane model.
Abstract Endometriosis is an oestrogen-dependent, inflammation-driven gynaecologic disorder causing severe disability. Endometriosis implants are characterized by unbalanced local oestrogen metabolism leading to hyperoestrogenism and aromatase up-regulation is one of main mechanism involved. Aromatase inhibitors such as letrozole or anastrozole use in young women are associated with severely side effects limiting their long-term clinical use. An endometriosis-targeted inhibition of local aromatase could be a viable alternative, although the role of the local inhibition of this enzyme is still unclear. Using a new ...
Source: J Cell Mol Med - June 14, 2019 Category: Molecular Biology Authors: Pluchino N, Poppi G, Yart L, Marci R, Wenger JM, Tille JC, Cohen M Tags: J Cell Mol Med Source Type: research

Obesity alters oestrogen metabolism and contributes to pulmonary arterial hypertension
This study has translational consequences as it suggests that oestrogen inhibitors may be especially beneficial in treating obese individuals with PAH. (Source: European Respiratory Journal)
Source: European Respiratory Journal - June 13, 2019 Category: Respiratory Medicine Authors: Mair, K. M., Harvey, K. Y., Henry, A. D., Hillyard, D. Z., Nilsen, M., MacLean, M. R. Tags: Pulmonary vascular disease Original Articles: Pulmonary hypertension Source Type: research

Development of an intravaginal ring delivering simultaneously anastrozole and levonorgestrel: a pharmacokinetic perspective.
This article describes the developmental pharmacokinetic (PK) aspects covering the characterization of in vitro release, preclinical IVR PK investigations in monkeys, and clinical PK considerations. An IVR for ATZ has been developed and investigated in healthy menstruating female cynomolgus monkeys showing effective in vivo release. PK data from the size-adapted IVR used in these animals can be translated into a human context as confirmed in human studies where predefined exposure levels of ATZ were reached. As ATZ may cause harm to the fetus, use of effective contraception has to be assured in women of childbearing potent...
Source: Drug Delivery - June 10, 2019 Category: Drugs & Pharmacology Tags: Drug Deliv Source Type: research

Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer
New England Journal of Medicine,Volume 380, Issue 23, Page 2282-2282, June 2019. (Source: New England Journal of Medicine)
Source: New England Journal of Medicine - June 5, 2019 Category: Internal Medicine Source Type: research

Temperature/pH-Triggered PNIPAM-Based Smart Nanogel System Loaded With Anastrozole Delivery for Application in Cancer Chemotherapy.
This study investigates the formulation optimization anastrozole (ANST)-loaded PNIPAM nanoparticle (NPs) prepared by solvent evaporation method for pH- and thermo-responsive drug delivery. Box-Behnken design (BBD) was implemented to observe the effect of selected process parameters on quality attributes product including particle size 110.15 nm, zeta potential - 11.02 mV, PDI 0.175, and drug loading 8.35% (DL). The statistical data was found to fit in the quadratic model and p value is less than 0.005. The thermo-responsive behavior of PNIPAM is evaluated on DLS and UV-Visible spectroscopy at elevated temp...
Source: AAPS PharmSciTech - June 4, 2019 Category: Drugs & Pharmacology Authors: Singh A, Vaishagya K, K Verma R, Shukla R Tags: AAPS PharmSciTech Source Type: research

Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial - ANZGOG 0903.
CONCLUSION: Although the objective response rate to anastrozole was relatively low, clinical benefit was observed in 44% of patients with ER/PR positive metastatic endometrial cancer and associated with an improvement in QOL. PMID: 31130288 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 23, 2019 Category: Cancer & Oncology Authors: Mileshkin L, Edmondson R, O'Connell RL, Sjoquist KM, Andrews J, Jyothirmayi R, Beale P, Bonaventura T, Goh J, Hall M, Clamp A, Green J, Lord R, Amant F, Alexander L, Carty K, Paul J, Scurry J, Millan D, Nottley S, Friedlander M, PARAGON study group Tags: Gynecol Oncol Source Type: research

A meta-analysis of clinical benefit rates for fulvestrant 500  mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer.
CONCLUSIONS: In postmenopausal patients with hormone receptor-positive ABC, fulvestrant 500 mg first-line was associated with significantly greater CBR (more patients benefiting from treatment) vs. comparator endocrine therapy. PMID: 31079343 [PubMed - as supplied by publisher] (Source: Breast Cancer)
Source: Breast Cancer - May 11, 2019 Category: Cancer & Oncology Authors: Robertson JFR, Jiang Z, Di Leo A, Ohno S, Pritchard KI, Ellis M, Bradbury I, Campbell C Tags: Breast Cancer Source Type: research

Surrogate threshold effect based on a meta-analysis for the predictive value of progression-free survival for overall survival in hormone receptor-positive, HER2-negative metastatic breast cancer
ConclusionsBased on the derived STE, it is possible to draw conclusions on a significant effect in OS for a hypothetical trial demonstrating an upper confidence limit of HRPFS 
Source: Breast Cancer Research and Treatment - May 7, 2019 Category: Cancer & Oncology Source Type: research

Association of Crystalline Retinopathy With Anastrozole
This case report describes a 69-year-old woman with a history of hypertension and breast cancer who presented with blurry vision in both eyes. (Source: JAMA Ophthalmology)
Source: JAMA Ophthalmology - May 1, 2019 Category: Opthalmology Source Type: research

Risk-reducing medications for primary breast cancer: a network meta-analysis.
CONCLUSIONS: For women with an above-average risk of developing breast cancer, CPAs can reduce the incidence of this disease. AIs appear to be more effective than SERMs (tamoxifen) in reducing the risk of developing breast cancer. AIs are not associated with an increased risk of endometrial cancer and thromboembolic events. However, long-term data on toxicities from tamoxifen are available while the follow-up toxicity data on unaffected women taking AIs is relatively short. Additional data from direct comparisons are needed to fully address the issues of breast cancer prevention by risk-reducing medications, with special r...
Source: Cochrane Database of Systematic Reviews - April 29, 2019 Category: General Medicine Authors: Mocellin S, Goodwin A, Pasquali S Tags: Cochrane Database Syst Rev Source Type: research

A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer
Tomás Pascual1,2, Miguel Martin3,4,5, Aranzazu Fernández-Martínez6, Laia Paré1,2, Emilio Alba4,5,7, Álvaro Rodríguez-Lescure4,8, Giuseppe Perrone9, Javier Cortés10,11, Serafín Morales12, Ana Lluch4,5,13,14,15, Ander Urruticoechea16, Blanca González-Farré2,17, Patricia Galván1, Pedro Jares17, Adela Rodriguez1, Nuria Chic1, Daniela Righi9, Juan Miguel Cejalvo1, Giuseppe Tonini9, Barbara Adamo1, Maria Vidal1, Patricia Villagrasa2, Montserrat Muñoz1 and Aleix Prat1,2* 1Medical Oncology Department, Hospital Clinic de Barcelona, Barcelona,...
Source: Frontiers in Oncology - April 26, 2019 Category: Cancer & Oncology Source Type: research

21-Gene Recurrence Score Assay Could Not Predict Benefit of Post-mastectomy Radiotherapy in T1-2 N1mic ER-Positive HER2-Negative Breast Cancer
Conclusion: This study showed that the 21-gene RS assay was not able to predict the benefit of PMRT for OS in women with T1-2 N1mic ER-positive HER2-negative breast cancer. However, further prospective larger sample-size trials are warranted to determine if a benefit exists. Introduction According to the latest Global Cancer Statistics 2018, breast cancer is still the most frequent cancer and the leading cause of cancer death among females worldwide (1). It is estimated that there will be about 2.1 million newly diagnosed female breast cancer cases and 627,000 cancer death in 2018 (1). The use of screening tests for ...
Source: Frontiers in Oncology - April 16, 2019 Category: Cancer & Oncology Source Type: research

Isolation of Antimicrobial Compounds From Cnestis ferruginea Vahl ex. DC (Connaraceae) Leaves Through Bioassay-Guided Fractionation
Conclusion In conclusion, aqueous extracts of C. ferruginea leaves showed antimicrobial activity due to the presence of hydroquinone and caffeic acid methyl ester. This supports its traditional use for infections and confirmed that the active molecules are water-soluble. Author Contributions KK, SP, LVP, and WL conceived and designed the experiments. SP, KK, M-RY, and J-GL performed the experiments. SP, LVP, WL, M-RY, J-GL, and Z-HJ analyzed the data. WL and Z-HJ contributed reagents, materials, and analysis tools. KK, SP, WL, M-RY, Z-HJ, and LVP contributed to the writing of the manuscript. All authors contributed to m...
Source: Frontiers in Microbiology - April 11, 2019 Category: Microbiology Source Type: research

Comparative Efficacy of CDK4/6 Inhibitors Plus Aromatase Inhibitors Versus Fulvestrant for the First-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer: A Network Meta-Analysis
ConclusionsWithin the limitations of this network meta-analysis, the comparison indicates that CDK4/6is plus AIs might represent a better option for HR+  ABC as a first-line endocrine treatment compared with fulvestrant. (Source: Targeted Oncology)
Source: Targeted Oncology - April 3, 2019 Category: Cancer & Oncology Source Type: research

Accelerated onset of retinal toxicity from hydroxychloroquine use with concomitant breast cancer therapy
Conclusion: Concomitant breast cancer therapy may have a synergistic effect with HCQ leading to accelerated retinal toxicity. As such potential acceleration is poorly understood, patients on HCQ who are treated with concomitant chemotherapy should be considered for more frequent retinal screenings to maximize safety and preservation of vision. (Source: Retinal Cases and Brief Reports)
Source: Retinal Cases and Brief Reports - March 30, 2019 Category: Opthalmology Tags: Case Report Source Type: research

Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer
New England Journal of Medicine,Volume 380, Issue 13, Page 1226-1234, March 2019. (Source: New England Journal of Medicine)
Source: New England Journal of Medicine - March 27, 2019 Category: Internal Medicine Authors: Rita S. Mehta William E. Barlow Kathy S. Albain Ted A. Vandenberg Shaker R. Dakhil Nagendra R. Tirumali Danika L. Lew Daniel F. Hayes Julie R. Gralow Hannah H. Linden Robert B. Livingston Gabriel N. Hortobagyi Source Type: research

[Reversible cerebral vasoconstriction syndrome associated with anastrozole: an unusual cause of high impact].
CONCLUSION: RCVS is difficult to diagnose given its wide array of symptoms and multifactorial etiology. In this case, RCVS plus SAH is associated with the use of anastrozole. So far there are no reported cases of aromatase inhibitors associated with this pathology and should be reported in the literature for pharmacovigilance. PMID: 30855709 [PubMed - in process] (Source: Revista de Neurologia)
Source: Revista de Neurologia - March 12, 2019 Category: Neurology Authors: Coral-Casas J, Ricaurte-Fajardo A, McCormick SJ, Baracaldo I, Jimenez CA, Mejia JA Tags: Rev Neurol Source Type: research

Localized Cutaneous Adverse Event Induced by Anastrozole as Adjuvant Treatment for Breast Cancer: A Case Report
We describe a rare case of a cutaneous adverse event that developed in a cancer-affected breast after aromatase inhibitor treatment. A 72-year-old postmenopausal female patient who was diagnosed with stage IA breast cancer received anastrozole as adjuvant treatment. Six months after the initiation of anastrozole, she developed an irregularly shaped purpuric plaque with several purpuric papules surrounding the postoperative scar on her left breast. Histological findings revealed capillary vessel proliferation and expansion, with hemorrhage in the superficial dermis. Immunohistochemistry of the skin biopsy specimen revealed ...
Source: Case Reports in Dermatology - March 7, 2019 Category: Dermatology Source Type: research

Retrospective Analysis of Treatment Patterns and Effectiveness of Palbociclib and Subsequent Regimens in Metastatic Breast Cancer.
This study examines physician practice patterns and treatment outcomes of palbociclib and subsequent therapies in a real-world setting. Methods: A retrospective chart review was conducted for consecutive patients with MBC who received palbociclib between February 2015 and August 2017 at the Alvin J. Siteman Cancer Center. Kaplan-Meier method was used to generate time-to-event curves and estimate median progression-free survival (mPFS). Log-rank test was used to compare differences. Results: A total of 200 patients, with a median age of 59.4 years and a follow-up of 19.5 months, were included. Palbociclib was most frequentl...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - February 24, 2019 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Breast cancer cell-induced platelet activation is compounded by tamoxifen and anastrozole in vitro
This study investigated platelet activation caused by Tamoxifen or Anastrozole-treated breast cancer cells in vitro.MCF7 and T47D cells were pre-treated with Tamoxifen or Anastrozole to mimic the effects of the drugs in vivo, and co-cultured with whole blood. (Source: Thrombosis Research)
Source: Thrombosis Research - February 23, 2019 Category: Hematology Authors: K. Pather, T. Dix-Peek, R. Duarte, N. Chetty, T.N. Augustine Tags: Full Length Article Source Type: research

Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome-Wide Association Study: Functional Epistatic Interaction between SLC38A7 and ALPPL2.
This article is protected by copyright. All rights reserved. PMID: 30648747 [PubMed - as supplied by publisher] (Source: Clinical Pharmacology and Therapeutics)
Source: Clinical Pharmacology and Therapeutics - January 16, 2019 Category: Drugs & Pharmacology Authors: Dudenkov TM, Liu D, Cairns J, Devarajan S, Zhuang Y, Ingle JN, Buzdar AU, Robson ME, Kubo M, Batzler A, Barman P, Jenkins GD, Carlson EE, Goetz MP, Northfelt DW, Moreno-Aspitia A, Desta Z, Reid JM, Kalari KR, Wang L, Weinshilboum RM Tags: Clin Pharmacol Ther Source Type: research